This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Malesci, A. Articles by Santoro, A. Search for Related Content PubMed PubMed Citation Articles by Malesci, A. Articles by Santoro, A.

Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer

Authors' Affiliations: Departments of ¹ Gastroenterology, ² Pathology, ³ Oncology, and ⁴ Surgery; ⁵ GI Research Laboratory, IRCCS Istituto Clinico Humanitas; Departments of ⁶ Internal Medicine, ⁷ Surgery, and ⁸ Pathology, University of Milan; and ⁹ Laboratory of Clinical Research in Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

Requests for reprints: Alberto Malesci, Department of Gastroenterology, IRCCS Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy. Phone: 39-2-8224-4542; Fax: 39-2-8224-4590; E-mail: alberto.malesci{at}humanitas.it.

Purpose: The outcome of patients with colorectal cancer is more favorable when the tumor exhibits high-frequency microsatellite instability (MSI). Although associated with earlier-stage tumors, MSI has been proposed as an independent predictor of survival. We tested the prognostic value of MSI in a large series of patients diagnosed with colorectal cancer in the last decade.

Experimental Design: The survival of 893 consecutive patients with colorectal cancer characterized by microsatellite status was analyzed. The 89 (10%) patients with MSI cancer were classified according to tumor mismatch repair (MMR) defect, MMR germ-line mutation, hMLH1 and p16 promoter methylation, BRAF and K-ras mutations, and frameshifts of target genes.

Results: The colorectal cancer–specific survival was significantly (P = 0.02) better in patients with MSI cancer than in those with stable tumor (MSS). MSI did not predict a significantly lower risk of cancer-related death if tumor stage was included in the multivariate analysis [hazard ratio, 0.72; 95% confidence interval (95% CI), 0.40-1.29; P = 0.27]. Instead, MSI was strongly associated with a decreased likelihood of lymph node (odds ratio, 0.31; 95% CI, 0.17-0.56; P < 0.001) and distant organ (odds ratio, 0.13; 95% CI, 0.05-0.33; P < 0.001) metastases at diagnosis, independently of tumor pathologic features. Molecular predictors of reduced metastatic risk, and then of more favorable prognosis, included TGFßRII mutation for all MSI tumors, hMSH2 deficiency for hereditary non-polyposis colorectal cancer, and absence of p16 methylation for sporadic hMLH1-deficient cancers.

Conclusions: Tumor MSI is a stage-dependent predictor of survival in patients with colorectal cancer. The decreased likelihood of metastases in patients with MSI cancer is associated with specific genetic and epigenetic changes of the primary tumor.

This article has been cited by other articles:

				I. Zlobec, K. Baker, L. M. Terracciano, and A. Lugli RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis Clin. Cancer Res., June 15, 2008; 14(12): 3798 - 3806. [Abstract] [Full Text] [PDF]

				I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569. [Abstract] [Full Text] [PDF]

				T. Watanabe, Y. Yamamoto, H. Yamada, T. Hayama, Y. Aoyagi, K. Nakamura, H. Shibuya, and T. Kobunai Survival in Microsatellite-Unstable Colorectal Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2516 - 2516. [Full Text] [PDF]

				A. Malesci, L. Laghi, and P. Bianchi Reply to the Letter to the Editor from Watanabe et al Clin. Cancer Res., April 15, 2008; 14(8): 2516 - 2516. [Full Text] [PDF]